CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, November 14, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science…

Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, September 11, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science…

Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance

CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,…

Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative…

CENTOGENE representatives are attending events in Brazil and Switzerland, and will be available to discuss Pharma, CRO, and Diagnostic collaboration…

Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,…

Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options

CAMBRIDGE, Mass. And ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG), the essential life science partner…

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads